EP3273975A4 - Künstlicher in-vitro-lymphknoten zur sensibilisierung und expansion von t-zellen für therapie und epitopkartierung - Google Patents

Künstlicher in-vitro-lymphknoten zur sensibilisierung und expansion von t-zellen für therapie und epitopkartierung Download PDF

Info

Publication number
EP3273975A4
EP3273975A4 EP16769745.7A EP16769745A EP3273975A4 EP 3273975 A4 EP3273975 A4 EP 3273975A4 EP 16769745 A EP16769745 A EP 16769745A EP 3273975 A4 EP3273975 A4 EP 3273975A4
Authority
EP
European Patent Office
Prior art keywords
sensitization
therapy
expansion
cells
lymph node
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16769745.7A
Other languages
English (en)
French (fr)
Other versions
EP3273975A1 (de
Inventor
Lea LOWENFELD
Brian J. Czerniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP3273975A1 publication Critical patent/EP3273975A1/de
Publication of EP3273975A4 publication Critical patent/EP3273975A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16769745.7A 2015-03-26 2016-03-25 Künstlicher in-vitro-lymphknoten zur sensibilisierung und expansion von t-zellen für therapie und epitopkartierung Withdrawn EP3273975A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138684P 2015-03-26 2015-03-26
US201562138969P 2015-03-26 2015-03-26
PCT/US2016/024146 WO2016154508A1 (en) 2015-03-26 2016-03-25 In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping

Publications (2)

Publication Number Publication Date
EP3273975A1 EP3273975A1 (de) 2018-01-31
EP3273975A4 true EP3273975A4 (de) 2018-10-17

Family

ID=56977770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16769745.7A Withdrawn EP3273975A4 (de) 2015-03-26 2016-03-25 Künstlicher in-vitro-lymphknoten zur sensibilisierung und expansion von t-zellen für therapie und epitopkartierung

Country Status (5)

Country Link
EP (1) EP3273975A4 (de)
JP (1) JP2018510644A (de)
CN (1) CN108289910A (de)
CA (1) CA2981033A1 (de)
WO (1) WO2016154508A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302539A4 (de) * 2015-05-22 2018-12-19 Brian J. Czerniecki Herstellung von injektionsfertigen mehrfachdosis-impfungen aus dendritischen zellen
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
EP3678701A4 (de) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182870A1 (en) * 2009-08-24 2011-07-28 Leen Ann M Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2012140127A2 (en) * 2011-04-13 2012-10-18 Immunicum Ab Method for priming of t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035282A1 (en) * 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
US8945922B2 (en) * 2008-09-08 2015-02-03 Riken Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way
US9114100B2 (en) * 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
AU2011304728A1 (en) * 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
US8741642B2 (en) * 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182870A1 (en) * 2009-08-24 2011-07-28 Leen Ann M Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2012140127A2 (en) * 2011-04-13 2012-10-18 Immunicum Ab Method for priming of t cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016154508A1 *
SONIA A PEREZ ET AL: "HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones", CANCER IMMUNOLOGY, IMMUNOTHE, SPRINGER, BERLIN/HEIDELBERG, vol. 50, no. 11, 1 January 2002 (2002-01-01), pages 615 - 624, XP009138053, ISSN: 0340-7004, [retrieved on 20011123], DOI: 10.1007/S002620100225 *
SOTIRIADOU R ET AL: "Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 85, no. 10, 16 November 2001 (2001-11-16), pages 1527 - 1534, XP002293865, ISSN: 0007-0920, DOI: 10.1054/BJOC.2001.2089 *

Also Published As

Publication number Publication date
WO2016154508A1 (en) 2016-09-29
CA2981033A1 (en) 2016-09-29
EP3273975A1 (de) 2018-01-31
WO2016154508A8 (en) 2018-03-15
CN108289910A (zh) 2018-07-17
JP2018510644A (ja) 2018-04-19

Similar Documents

Publication Publication Date Title
IL275433A (en) Artificial antigen-presenting cells and methods of use
EP3273987A4 (de) Künstliches lymphknotenverfahren in vitro zur sensibilisierung und expansion von t-zellen für therapie und epitopkartierung
EP3328399A4 (de) Modifizierte zellen und therapieverfahren
EP3601528A4 (de) Zellen und verfahren zur verwendung und herstellung derselben
EP3528823A4 (de) Deterministische laterale verschiebung bei der herstellung von zellen und zusammensetzungen für therapeutische verwendungen
EP3407901A4 (de) Expansion und differenzierung von innenohrunterstützenden zellen und verfahren zur verwendung davon
EP3568467A4 (de) Modifizierte t-zellen und verfahren zu deren verwendung
EP3273976A4 (de) Modifizierte t-zellen und verfahren zur herstellung und verwendung davon
EP3122181A4 (de) Zusammensetzungen und verfahren zur ex-vivo-vermehrung von menschlichen hämatopoietischen stamm-/vorläuferzellen
GB201707048D0 (en) Expansion of gamma delta cells, compositions, and methods of use thereof
DK3215611T3 (da) Peptid-medieret indgivelse af rna-guidet endonuklease i celler
EP3094720A4 (de) Zusammensetzungen und verfahren zur herstellung von atemwegszellen
EP3359650A4 (de) Aktivierung und expansion von zellen
IL280240A (en) T-cells containing nef and methods for their production
EP3134409A4 (de) Verbindungen und verwendung davon in der expansion von hämatopoietischen stammzellen und/oder hämatopoietischen vorläuferzellen
EP3274079A4 (de) Künstliche plazenta und verfahren zur herstellung
AU2018288863A1 (en) Methods for producing regulatory immune cells and uses thereof
EP3347449A4 (de) Zellexpansionsverfahren und therapeutische zusammensetzungen
EP3420075A4 (de) Erzeugung von krebsstammzellen und verwendung davon
NI201500177A (es) Formulación en perlas de cisteamina de liberación retardada
EP3518943A4 (de) Verfahren zur adaptiven zelltherapie
EP2970885A4 (de) Expansion adulter stammzellen in vitro
EP3645708A4 (de) Zusammensetzungen und verfahren zur adoptiven zelltherapie für krebs
EP3217989A4 (de) Zusammensetzungen und verfahren zur stimulierung und erweiterung von t-zellen
EP3273975A4 (de) Künstlicher in-vitro-lymphknoten zur sensibilisierung und expansion von t-zellen für therapie und epitopkartierung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CZERNIECKI, BRIAN, J.

Inventor name: LOWENFELD, LEA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180914

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0784 20100101ALI20180911BHEP

Ipc: A61K 39/00 20060101AFI20180911BHEP

Ipc: A61K 38/00 20060101ALI20180911BHEP

Ipc: C12N 5/0783 20100101ALI20180911BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190604

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210910